---
schema_version: "secwatch.filing_event.v1"
accession: "0001378325-25-000008"
form_type: "8-K"
ticker: "CV"
cik: "0001378325"
company_name: "CapsoVision, Inc"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:58:20.067922+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CapsoVision Q2 revenue $3.3M (+17% YoY); IPO closes raising $23.4M

## Summary
- Revenue $3.3M, up 17% YoY, driven by higher CapsoCam Plus capsule sales.
- Gross profit $1.8M (55% margin) vs. $1.6M (56%) in Q2 2024.
- Operating expenses $6.5M, down $0.4M from prior year due to reduced clinical trial costs.
- Closed IPO on July 3, 2025, net proceeds of $23.4M; cash was $1.1M at June 30.
- Filed 510(k) for CapsoCam Colon in June 2025; AI module addition targeted for FDA approval.

## SEC filing metadata
- accession: 0001378325-25-000008
- form_type: 8-K
- ticker: CV
- cik: 0001378325
- company_name: CapsoVision, Inc
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1378325/000137832525000008/0001378325-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1378325/000137832525000008/cv-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001378325-25-000008
- JSON: https://secwatch.observer/filing/0001378325-25-000008.json
- Plain text: https://secwatch.observer/filing/0001378325-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.